Molecular Cancer (Mar 2018)

Loss of miR-204 expression is a key event in melanoma

  • Marco Galasso,
  • Carl Morrison,
  • Linda Minotti,
  • Fabio Corrà,
  • Carlotta Zerbinati,
  • Chiara Agnoletto,
  • Federica Baldassari,
  • Matteo Fassan,
  • Armando Bartolazzi,
  • Andrea Vecchione,
  • Gerard J. Nuovo,
  • Gianpiero Di Leva,
  • Stefania D’Atri,
  • Ester Alvino,
  • Maurizio Previati,
  • Brian J. Nickoloff,
  • Carlo M. Croce,
  • Stefano Volinia

DOI
https://doi.org/10.1186/s12943-018-0819-8
Journal volume & issue
Vol. 17, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Cutaneous melanoma (CM) is a malignancy with increasing occurrence. Its microRNA repertoire has been defined in a number studies, leading to candidates for biological and clinical relevance: miR-200a/b/c, miR-203, miR-205, miR-204, miR-211, miR-23b and miR-26a/b. Our work was aimed to validate the role of these candidate miRNAs in melanoma, using additional patients cohorts and in vitro cultures. miR-26a, miR-204 and miR-211 were more expressed in normal melanocytes, while miR-23b, miR-200b/c, miR-203 and miR-205 in epidermis and keratinocytes. None of the keratinocyte-related miRNAs was associated with any known mutation or with clinical covariates in melanoma. On the other hand, the loss of miR-204 was enriched in melanomas with NRAS sole mutation (Fisher exact test, P = 0.001, Log Odds = 1.67), and less frequent than expected in those harbouring CDKN2A mutations (Fisher exact test, P = 0.001, Log Odds − 1.09). Additionally, miR-204 was associated with better prognosis in two independent melanoma cohorts and its exogenous expression led to growth impairment in melanoma cell lines. Thus, miR-204 represents a relevant mechanism in melanoma, with potential prognostic value and its loss seems to act in the CDKN2A pathway, in cooperation with NRAS.

Keywords